199 related articles for article (PubMed ID: 36682472)
1. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Matin A; Smith BH; Mangaonkar A; Duffy DJ; Wolf R; Alkhateeb H; Shah MV; Hogan WJ; Litzow MR
Transplant Cell Ther; 2023 May; 29(5):324.e1-324.e6. PubMed ID: 36682472
[TBL] [Abstract][Full Text] [Related]
2. Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients.
Liu YC; Gau JP; Hong YC; Yu YB; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
Ann Hematol; 2012 Dec; 91(12):1953-8. PubMed ID: 22869091
[TBL] [Abstract][Full Text] [Related]
3. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
4. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation.
Freyer CW; Fradley M; Madnick D; Carver JR; Frey NV; Gill SI; Ky B; Luger SM; Martin ME; McCurdy SR; O'Quinn R; Perl AE; Stadtmauer EA; Loren AW
Transplant Cell Ther; 2021 Nov; 27(11):934.e1-934.e6. PubMed ID: 34339867
[TBL] [Abstract][Full Text] [Related]
7. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
8. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation.
Kubo H; Imataki O; Fukumoto T; Oku M; Ishida T; Kubo YH; Kida JI; Uemura M; Fujita H; Ohno H; Ide M; Ohnishi H; Kadowaki N
Transplant Cell Ther; 2021 Nov; 27(11):949.e1-949.e8. PubMed ID: 34333179
[TBL] [Abstract][Full Text] [Related]
11. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
12. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation.
Patel SS; Ahn KW; Khanal M; Bupp C; Allbee-Johnson M; Majhail NS; Hamilton BK; Rotz SJ; Hashem H; Beitinjaneh A; Lazarus HM; Krem MM; Prestidge T; Bhatt NS; Sharma A; Gadalla SM; Murthy HS; Broglie L; Nishihori T; Freytes CO; Hildebrandt GC; Gergis U; Seo S; Wirk B; Pasquini MC; Savani BN; Sorror ML; Stadtmauer EA; Chhabra S
Transplant Cell Ther; 2022 Jun; 28(6):310-320. PubMed ID: 35314376
[TBL] [Abstract][Full Text] [Related]
13. Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients.
Rhodes M; Lautz T; Kavanaugh-Mchugh A; Manes B; Calder C; Koyama T; Liske M; Parra D; Frangoul H
Bone Marrow Transplant; 2005 Jul; 36(2):139-44. PubMed ID: 15908968
[TBL] [Abstract][Full Text] [Related]
14. Large pericardial effusion as a complication in adults undergoing SCT.
Norkin M; Ratanatharathorn V; Ayash L; Abidi MH; Al-Kadhimi Z; Lum LG; Uberti JP
Bone Marrow Transplant; 2011 Oct; 46(10):1353-6. PubMed ID: 21113188
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation.
Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Tzeng CH
Br J Haematol; 2015 Jun; 169(5):737-45. PubMed ID: 25818840
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease.
Mupfudze TG; Meyer C; Preussler JM; Mau LW; Bolon YT; Steinert P; Arnold SD; Saber W; Krishnamurti L
Transplant Cell Ther; 2021 Aug; 27(8):685.e1-685.e8. PubMed ID: 33895405
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Beta-Blocker Use at the Time of Hematopoietic Cell Transplantation on the Development of Acute and Chronic Graft-Versus-Host Disease.
Patel A; Murthy GSG; Hamadani M; Szabo A; Knight JM
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):209-216. PubMed ID: 34780786
[TBL] [Abstract][Full Text] [Related]
18. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD; Koff JL; Khoury HJ; Langston AA; Zimring JC; Roback JD; Giver CR
Biol Blood Marrow Transplant; 2018 May; 24(5):973-982. PubMed ID: 29307717
[TBL] [Abstract][Full Text] [Related]
19. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
20. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Auletta JJ; Badawy SM; Bhatt N; Bhatt VR; Cahn JY; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Gale RP; Hashem H; Hashmi S; Hematti P; Hong S; Hossain NM; Inamoto Y; Lekakis LJ; Modi D; Patel S; Sharma A; Solomon S; Couriel DR
Transplant Cell Ther; 2022 Oct; 28(10):712.e1-712.e8. PubMed ID: 35863740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
